Detalles de la búsqueda
1.
Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility.
J Med Genet
; 58(12): 853-858, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33168572
2.
Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.
Hered Cancer Clin Pract
; 19(1): 24, 2021 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33836815
3.
Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.
Genet Med
; 22(5): 831-839, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31996782
4.
The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
Med J Aust
; 212(2): 72-81, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31595523
5.
A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
Value Health
; 22(8): 854-862, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31426925
6.
Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.
Breast J
; 25(1): 34-40, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30525267
7.
Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
Genet Med
; 20(10): 1145-1156, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29323669
8.
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
BMC Cancer
; 18(1): 254, 2018 03 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29506471
9.
Making Sense of SNPs: Women's Understanding and Experiences of Receiving a Personalized Profile of Their Breast Cancer Risks.
J Genet Couns
; 27(3): 702-708, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29168041
10.
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.
Hum Mol Genet
; 24(18): 5345-55, 2015 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26130695
11.
Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial.
Genet Med
; 19(4): 448-456, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27684037
12.
Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab.
Genet Med
; 19(1): 30-35, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27171545
13.
Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study.
BMC Cancer
; 17(1): 491, 2017 Jul 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28720130
14.
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
J Med Genet
; 53(1): 34-42, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26534844
15.
Acute kidney injury is under-recognised and under-reported in hospitalised patients in Australia.
Intern Med J
; 47(12): 1451-1454, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29224207
16.
Monogenic and polygenic determinants of sarcoma risk: an international genetic study.
Lancet Oncol
; 17(9): 1261-71, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27498913
17.
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
Breast Cancer Res
; 18(1): 15, 2016 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26857456
18.
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat
; 157(2): 319-327, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27117159
19.
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Gynecol Oncol
; 140(2): 199-203, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26723501
20.
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Proc Natl Acad Sci U S A
; 110(48): 19489-94, 2013 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-24218601